<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g292" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-287.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
	<a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-262.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-279.html" >Diseases Characterized by Vaginal Discharge</a><span class="carrot"> > </span>
                    <a href="lv-279.html" >Vulvovaginal Candidiasis</a><span class="carrot"> > </span>
                    <a href="lv-287.html" >Complicated VVC</a><span class="carrot"> > </span>Nonalbicans VVC
            </div>
            </br><h4 class="sgc-1" id="sigil_toc_id_292">
 Nonalbicans VVC
</h4>
<p>
 The optimal treatment of nonalbicans VVC remains unknown. Options include longer duration of therapy (7&ndash;14&nbsp;days) with a nonfluconazole azole drug (oral or topical) as first-line therapy. If recurrence occurs, 600 mg of boric acid in a gelatin capsule is recommended, administered vaginally once daily for 2 weeks. This regimen has clinical and mycologic eradication rates of approximately 70% (380). If symptoms recur, referral to a specialist is advised.
</p>

            </div>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

